Tag

Lpa

All articles tagged with #lpa

health12 days ago•4 min saved

Hidden Lipoprotein(a) May Raise Heart Risk Even With Normal Tests

Lp(a) is a genetically determined cholesterol particle linked to higher risk of heart attack and stroke that standard tests miss. Lifestyle and most cholesterol meds don’t meaningfully lower Lp(a); newer gene-silencing therapies show large reductions in Lp(a) in trials and could reduce events if confirmed. Testing is often advised for those with a family history or unexplained risk, but for now heart health still hinges on managing LDL cholesterol, blood pressure, smoking, activity, and diet.

via SciTechDaily|

#cardiovascular-risk #genetics #health

health29 days ago•6 min saved

Lp(a) bets: Trio of pharma giants chase a genetic risk into a heart-blockbuster

Novartis, Amgen and Eli Lilly are racing to prove that lowering Lipoprotein(a) can prevent heart attacks. They’re in late-stage trials of pelacarsen, olpasiran and lepodisiran, which have achieved >80% reductions in Lp(a) so far, but it’s unclear if this lowers events; readouts are due mid-year for Novartis, 2027 for Amgen, and 2029 for Lilly. A successful outcome could unlock a multi-billion-dollar market—about $5.6 billion annually by 2032—though doctors say screening for Lp(a) remains uncommon and uptake will depend on solid outcome data.

via CNBC|

#cardiovascular-disease #health #lepodisiran

health1 month ago•4 min saved

Cholesterol Risk: Only a Blood Test Tells If It's Too High

Cardiologists say the only reliable way to know if cholesterol is too high is a blood test. High LDL and low HDL increase heart-disease risk, and new guidelines call for regular lipid screening—from childhood through adulthood (every five years) and measuring lipoprotein(a) at least once. Most people have no early symptoms, so routine testing plus healthy lifestyle choices (diet, exercise, no smoking) are key; signs like chest pain or shortness of breath usually appear only after disease has progressed.

via Prevention|

#cholesterol #health #ldl

health-and-medicine1 month ago•8 min saved

New cholesterol guidelines push earlier, personalized heart-disease prevention

The 2026 ACC/AHA dyslipidemia guidelines call for earlier, more personalized cholesterol screening (even in children for familial hypercholesterolemia), broader risk assessment including genetic factors like Lp(a), and introduce a new PREVENT calculator to estimate 10- and 30-year cardiovascular risk, with expanded treatment options and lower LDL targets to prevent heart disease decades down the line.

via ScienceDaily|

#cardiovascular-risk #cholesterol #health-and-medicine

health2 months ago•265 min saved

New Cholesterol Guidelines Emphasize Early Screening and Clear LDL Goals

The 2026 cholesterol guidelines from the ACC and AHA expand risk assessment to ages 30–79, emphasize lifetime risk, restore explicit LDL targets (<100 mg/dL for low risk, <70 mg/dL for higher risk, <55 mg/dL for very high risk), add one-time Lp(a) testing to uncover genetic risk, and encourage earlier lifestyle changes and targeted therapies to prevent heart disease.

via AOL.com|

#cholesterol #health #ldl

health2 months ago•6 min saved

Cholesterol guidelines urge earlier screening and expanded biomarker testing

New cholesterol guidelines urge starting screening in your 30s and using lifetime risk (via the PREVENT calculator) alongside 10-year risk to guide treatment. Targets are LDL <100 mg/dL for most, <70 mg/dL for high-risk individuals, and <55 mg/dL for those with existing heart disease, with statins considered earlier; the guidance also recommends apoB testing after LDL goals and universal lipoprotein(a) testing once in adulthood, plus calcium scoring for those at borderline/intermediate risk, all aiming to reduce lifetime LDL exposure and prevent cardiovascular events.

via NBC News|

#cholesterol #guidelines #health

health2 months ago•10 min saved

Early Lipid-Lowering Urged: New Guidelines Target 30-Year-Olds

New cardiovascular guidelines urge starting lipid management as early as age 30, using the PREVENT risk calculator and lower LDL targets (under 100 mg/dL for lower-risk, under 70 mg/dL for high risk, and under 55 mg/dL for very high risk). They endorse lifestyle changes, consider coronary calcium scans and biomarkers like Lp(a) and ApoB to guide therapy, and include statins and, in some cases, PCSK9 inhibitors as part of a broader prevention strategy.

via statnews.com|

#coronary-calcium-scan #health #ldl

health4 months ago•4 min saved

Progress Nears in Developing Drug to Reduce Artery-Clogging Particle

Researchers are nearing the completion of clinical trials for five experimental drugs aimed at lowering lipoprotein(a), a genetic particle linked to artery clogging and heart disease, with results expected in 2026. These drugs could significantly impact the treatment of a condition affecting about 20% of the global population, though cost and public awareness remain challenges.

via The Washington Post|

#cardiovascular-disease #clinical-trials #experimental-drugs

health8 months ago•3 min saved

Lipoprotein(a): A Key Indicator for Heart Disease Risk and Prevention

A Staten Island cardiologist highlights the importance of testing for lipoprotein(a) or Lp(a), a genetic cholesterol marker that increases the risk of heart attack and stroke, which is often overlooked and not affected by diet or exercise, emphasizing early detection and management for better heart health.

via SILive.com|

#cholesterol #health #heart-disease

health11 months ago•3 min saved

Obicetrapib Reduces Cholesterol and Heart Attack Risk in 12 Weeks

A new pill called Obicetrapib significantly lowers 'bad' LDL cholesterol and lipoprotein(a) levels in just 12 weeks, offering a promising treatment for high-risk heart patients, with results showing over 30% reduction and good tolerability.

via SciTechDaily|

#cholesterol #health #heart-disease

health-medicine2 years ago•5 min saved

"Uncovering Silent Threats: The Hidden Dangers of Vascular Disease and Cholesterol"

Doctors warn that up to 65 million Americans may be at risk of deadly stroke or heart attack due to high levels of a specific type of cholesterol called lipoprotein(a), which is determined almost entirely by genetics and currently has no approved treatments. High levels of Lp(a) can lead to a two- to three-fold higher risk of heart attack and a nearly two-fold increased risk of stroke, often occurring at a relatively young age. Comprehensive cholesterol testing is being called for to detect high levels of Lp(a) and help patients mitigate their risks, while pharmaceutical companies are developing treatments to lower Lp(a) levels.

via Daily Mail|

#cardiovascular-disease #cholesterol #health-medicine

health2 years ago•5 min saved

The Hidden Red Flag in Heart Attack Risk Assessment

Lipoprotein(a) or Lp(a) is a genetic risk factor that greatly increases the chances of a heart attack when present in high levels in the blood. Lp(a) causes atherosclerosis, inflammation, and increases the risk of clotting, making it a triple threat for heart disease. Approximately 20% of the population, particularly Black and South Asian Americans, are at risk due to Lp(a), yet fewer than 1% of Americans have had their levels checked. While there is currently no therapeutic available to directly reduce Lp(a), testing levels can help individuals mitigate overall cardiovascular risk by focusing on reducing other risk factors. Researchers are working on developing drugs to treat high Lp(a) levels, and clinical trials are underway.

via New York Post |

#cardiovascular-health #genetic-risk #health

health2 years ago•6 min saved

"The Overlooked Red Flag in Assessing Heart Attack Risk, According to Doctors"

Lipoprotein(a) or Lp(a) is a protein that significantly increases the risk of heart attack when present in high levels in the blood. Lp(a) causes atherosclerosis, inflammation, and increases the risk of clotting, making it a triple threat for heart disease. Approximately 20% of the population, particularly Black and South Asian Americans, are at risk due to Lp(a), yet fewer than 1% of Americans have had their levels checked. While there is currently no therapeutic available to directly reduce Lp(a), it is important to reduce other cardiovascular risk factors. Testing Lp(a) levels can help individuals mitigate overall risk and make informed decisions about their health. Researchers are working on developing drugs to treat high Lp(a) levels, and lipoprotein apheresis is available for a small number of high-risk patients.

via Fox News|

#cardiovascular-health #genetic-risk-factor #health

health2 years ago•3 min saved

"Groundbreaking Drug Slashes Heart Disease Risk by 96%"

An experimental drug called lepodisiran has shown promising results in reducing blood levels of lipoprotein(a) (Lp(a)), a currently untreatable risk factor for heart disease. In a phase 1 trial, a single injection of lepodisiran lowered participants' high Lp(a) levels by as much as 96% from their baseline. Lepodisiran works by interfering with the genetic material that produces Lp(a), offering a potential solution for individuals with high Lp(a) levels who are unable to reduce this risk factor through lifestyle changes. Further trials are needed to confirm the drug's safety and effectiveness, but the initial results are encouraging.

via Freethink|

#experimental-drug #genetics #health